Polymeric Nanoparticle Technologies for Oral Drug Delivery

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 10, 2014, Pages 1605-1610

  Pridgen, Eric M ^a   Alexis, Frank ^b   Farokhzad, Omid C ^c,d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AMRL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

FcRn; GI; IF; Intestinal Absorption; M cell; Mucoadhesives; NP; Oral Delivery; Polymeric Nanoparticles

Indexed keywords

BIOLOGICAL PRODUCT; CHITOSAN; CUBILIN; CYANOCOBALAMIN; FC RECEPTOR; MACROGOL; MUCOADHESIVE; NANOCARRIER; PENETRATION ENHANCING AGENT; POLYACRYLIC ACID; POLYMER; UNCLASSIFIED DRUG; VITAMIN B12 RECEPTOR; VITAMIN RECEPTOR; DRUG CARRIER; NANOPARTICLE;

ACTIVE TRANSPORT; ARTICLE; CHEMICAL MODIFICATION; DEAMINATION; DENDRITIC CELL; DRUG ABSORPTION; DRUG HYDROLYSIS; DRUG TRANSPORT; ENZYMATIC DEGRADATION; EPITHELIUM; EPITHELIUM CELL; INTESTINE ABSORPTION; INTESTINE EPITHELIUM; LAMINA PROPRIA; MEDICATION COMPLIANCE; MUCUS; OXIDATION; PARTICLE SIZE; PERMEABILITY BARRIER; STOMACH PH; STOMACH SECRETION; SURFACE PROPERTY; TIGHT JUNCTION; TRANSCYTOSIS; HUMAN; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; DRUG CARRIERS; HUMANS; NANOPARTICLES; POLYMERS;

EID: 84908094310     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.06.018     Document Type: Article

References (71)

1. Aggarwal S. What's fueling the biotech engine-2012 to 2013. Nat Biotechnol 2014, 32:32-39.
2. Liu G., Franssen E., Fitch M.I., et al. Patient preferences for oral versus intravenous palliative chemotherapy. JClin Oncol 1997, 15:110-115.
3. Borner M.M., Schoffski P., de Wit R., et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002, 38:349-358.
4. Peppas N.A., Kavimandan N.J. Nanoscale analysis of protein and peptide absorption: insulin absorption using complexation and pH-sensitive hydrogels as delivery vehicles. Eur J Pharm Sci Off J Eur Fed Pharm Sci 2006, 29:183-197.
5. Mo R., Jiang T., Di J., et al. Emerging micro- and nanotechnology based synthetic approaches for insulin delivery. Chem Soc Rev 2014, 43:3595.
6. Galindo-Rodriguez S., Allemann E., Fessi H., et al. Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of invivo studies. Crit Rev Ther Drug Carr Syst 2005, 22:419-464.
7. Pridgen E., Langer R., Farokhzad O. Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. Nanomedicine (Lond) 2007, 2:669-680.
8. Mansour H.M., Rhee Y.-S., Wu X. Nanomedicine in pulmonary delivery. Int J Nanomed 2009, 4:299-319.
9. Hrkach J., Von Hoff D., Ali M.M., et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012, 4:128ra39.
10. Davis M.E., Chen Z.G., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7:771-782.
11. Bilati U., Allémann E., Doelker E. Nanoprecipitation versus emulsion-based techniques for the encapsulation of proteins into biodegradable nanoparticles and process-related stability issues. AAPS PharmSciTech 2005, 6:E594-E604.
12. Kamaly N., Xiao Z., Valencia P.M., et al. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev 2012, 41:2971.
13. Valencia P.M., Pridgen E.M., Rhee M., et al. Microfluidic platform for combinatorial synthesis and optimization of targeted nanoparticles for cancer therapy. ACS Nano 2013, 7:10671-10680.
14. Yu M.K., Park J., Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2012, 2:3-44.
15. Chen M.-C., Sonaje K., Chen K.-J., et al. Areview of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials 2011, 32:9826-9838.
16. Kararli T. Comparison of the gastrointestinal anatomy, physiology, and bio- chemistry of humans and commonly used laboratory-animals. Biopharm Drug Dispos 1995, 16:351-380.
17. Sood A., Panchagnula R. Peroral route: an opportunity for protein and peptide drug delivery. Chem Rev 2001, 101:3275-3304.
18. Ganapathy V., Gupta N., Martindale R. Protein digestion and absorption. Physiology of the gastrointestinal tract 2006, Academic Press, Burlington. 4th ed.
19. Johnson L., Christensen J., Jackson M., et al. Physiology of the gastrointestinal tract 1987, Raven Press, New York.
20. Ensign L.M., Cone R., Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev 2012, 64:557-570.
21. Atuma C., Strugala V., Allen A., et al. The adherent gastrointestinal mucus gel layer: thickness and physical state invivo. Am J Physiol Gastrointest Liver Physiol 2001, 280:G922-G929.
22. Mitic L.L., Van Itallie C.M., Anderson J.M. Molecular physiology and pathophysiology of tight junctions I. Tight junction structure and function: lessons from mutant animals and proteins. Am J Physiol Gastrointest Liver Physiol 2000, 279:G250-G254.
23. Tuma P.L., Hubbard A.L. Transcytosis: crossing cellular barriers. Physiol Rev 2003, 83:871-932.
24. Carino G.P., Mathiowitz E. Oral insulin delivery. Adv Drug Deliv Rev 1999, 35:249-257.
25. Lowe P.J., Temple C.S. Calcitonin and insulin in isobutylcyanoacrylate nanocapsules-protection against proteases and effect on intestinal absorption in rats. JPharm Pharmacol 1994, 46:547-552.
26. Damge C., Vranckx H., Balschmidt P., et al. Poly (alkyl cyanoacrylate) nanospheres for oral administration of insulin. JPharm Sci 1997, 86:1403-1409.
27. Smart J. The basics and underlying mechanisms of mucoadhesion. Adv Drug Deliv Rev 2005, 57:1556-1568.
28. Chen M.-C., Mi F.-L., Liao Z.-X., et al. Recent advances in chitosan-based nanoparticles for oral delivery of macromolecules. Adv Drug Deliv Rev 2013, 65:865-879.
29. Makhlof A., Werle M., Tozuka Y., et al. Amucoadhesive nanoparticulate system for the simultaneous delivery of macromolecules and permeation enhancers to the intestinal mucosa. JControl Release 2011, 149:81-88.
30. Furtado S., Abramson D., Burrill R., et al. Oral delivery of insulin loaded poly(fumaric-co-sebacic) anhydride microspheres. Int J Pharm 2008, 347:149-155.
31. Sonaje K., Lin Y.-H., Juang J.-H., et al. Invivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials 2009, 30:2329-2339.
32. Sonaje K., Chuang E.-Y., Lin K.-J., et al. Opening of epithelial tight junctions and enhancement of paracellular permeation by chitosan: microscopic, ultrastructural, and computed-tomographic observations. Mol Pharm 2012, 9:1271-1279.
33. Yeh T.-H., Hsu L.-W., Tseng M.T., et al. Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening. Biomaterials 2011, 32:6164-6173.
34. Bakhru S.H., Furtado S., Morello A.P., et al. Oral delivery of proteins by biodegradable nanoparticles. Adv Drug Deliv Rev 2013, 65:811-821.
35. Macdonald T., Monteleone G. Immunity, inflammation, and allergy in the gut. Science 2005, 307:1920-1925.
36. Jang M.H., Kweon M.-N., Iwatani K., et al. Intestinal villous M cells: an antigen entry site in the mucosal epithelium. Proc Natl Acad Sci U S A 2004, 101:6110-6115.
37. Des Rieux A., Fievez V., Théate I., et al. An improved invitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells. Eur J Pharm Sci 2007, 30:380-391.
38. Des Rieux A., Fievez V., Garinot M., et al. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. JControl Release 2006, 116:1-27.
39. Eldridge J.H., Hammond C.J., Meulbroek J.A., et al. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches. JControl Release 1990, 11:205-214.
40. Clark M., Jepson M.A., Hirst B.H. Exploiting M cells for drug and vaccine delivery. Adv Drug Deliv Rev 2001, 50:81-106.
41. Porta C., James P.S., Phillips A.D., et al. Confocal analysis of fluorescent bead uptake by mouse Peyer's patch follicle-associated M cells. Exp Physiol 1992, 77:929-932.
42. Brayden D.J. Oral vaccination in man using antigens in particles: current status. Eur J Pharm Sci 2001, 14:183-189.
43. De Jesus M., Ostroff G.R., Levitz S.M., et al. Apopulation of Langerin-positive dendritic cells in murine Peyer's patches involved in sampling β-glucan microparticles. PLoS One 2014, 9:e91002.
44. Khafagy E.-S., Morishita M., Onuki Y., et al. Current challenges in non-invasive insulin delivery systems: a comparative review. Adv Drug Deliv Rev 2007, 59:1521-1546.
45. Fievez V., Plapied L., des Rieux A., et al. Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination. Eur J Pharm Biopharm 2009, 73:16-24.
46. Petrus A.K., Fairchild T.J., Doyle R.P. Traveling the vitamin B12 pathway: oral delivery of protein and peptide drugs. Angew Chem Int Ed Engl 2009, 48:1022-1028.
47. Chalasani K.B., Russell-Jones G.J., Jain A.K., et al. Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles. JControl Release 2007, 122:141-150.
48. Chalasani K.B., Russell-Jones G.J., Yandrapu S.K., et al. Anovel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin. JControl Release 2007, 117:421-429.
49. Fowler R., Vllasaliu D., Trillo F.F., et al. Nanoparticle transport in epithelial cells: pathway switching through bioconjugation. Small 2013, 9:3282-3294.
50. Yoshida M., Claypool S.M., Wagner J.S., et al. Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity 2004, 20:769-783.
51. Dickinson B.L., Badizadegan K., Wu Z., et al. Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. JClin Invest 1999, 104:903-911.
52. Israel E.J., Taylor S., Wu Z., et al. Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells. Immunology 1997, 92:69-74.
53. Raghavan M., Gastinel L.N., Bjorkman P.J. The class I major histocompatibility complex related Fc receptor shows pH-dependent stability differences correlating with immunoglobulin binding and release. Biochemistry 1993, 32:8654-8660.
54. Lalezari D. Gastrointestinal pH profile in subjects with irritable bowel syndrome. Ann Gastroenterol 2012, 25:333.
55. Casey J.R., Grinstein S., Orlowski J. Sensors and regulators of intracellular pH. Nat Rev Mol Cell Biol 2010, 11:50-61.
56. Pridgen E.M., Alexis F., Kuo T.T., et al. Transepithelial transport of Fc-targeted nanoparticles by the neonatal Fc receptor for oral delivery. Sci Transl Med 2013, 5:213ra167.
57. Cochran E., Musso C., Gorden P. The use of U-500 in patients with extreme insulin resistance. Diabetes Care 2005, 28:1240-1244.
58. Von Pawel J., Gatzemeier U., Pujol J.L., et al. Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. JClin Oncol 2001, 19:1743-1749.
59. James R., Blanco C., Farina C. Savings in staff time as a result of switching from de Gramont to oral capecitabine for patients with advanced colorectal cancer. Eur J Cancer 2003, 1(Suppl 5):S83.
60. Yabroff K., Warren J., Knopf K., et al. Estimating patient time costs associated with colorectal cancer care. Med Care 2005, 43:640-648.
61. De Portu S., Mantovani L.G., Ravaioli A., et al. Cost analysis of capecitabine vs 5-fluorouracil-based treatment for metastatic colorectal cancer patients. JChemother 2010, 22:125-128.
62. Jansman F., Postma M., van Hartskamp D., et al. Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in The Netherlands. Clin Ther 2004, 26:579-589.
63. Ward S., Kaltenthaler E., Cowan J., et al. The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. Br J Cancer 2006, 95:27-34.
64. Bisht S., Feldmann G., Koorstra J.-B.M., et al. Invivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities. Mol Cancer Ther 2008, 7:3878-3888.
65. Attili-Qadri S., Karra N., Nemirovski A., et al. Oral delivery system prolongs blood circulation of docetaxel nanocapsules via lymphatic absorption. Proc Natl Acad Sci U S A 2013, 110:17498-17503.
66. Lamprecht A. Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. JPharmacol Exp Ther 2005, 315:196-202.
67. Wilson D.S., Dalmasso G., Wang L., et al. Orally delivered thioketal nanoparticles loaded with TNF-α-siRNA target inflammation and inhibit gene expression in the intestines. Nat Mater 2010, 9:923-928.
68. Yin L., Song Z., Qu Q., et al. Supramolecular self-assembled nanoparticles mediate oral delivery of therapeutic TNF-α siRNA against systemic inflammation. Angew Chem Int Ed Engl 2013, 52:5757-5761.
69. Davis M.E., Zuckerman J.E., Choi C.H.J., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
70. Wang A.Z., Langer R., Farokhzad O.C. Nanoparticle delivery of cancer drugs. Annu Rev Med 2012, 63:185-198.
71. Brogden R.N., Heel R.C. Human insulin. A review of its biological activity, pharmacokinetics and therapeutic use. Drugs 1987, 34:350-371.